Unresectable Breast Cancer
6 clinical trials · Condition
◉ Watch Unresectable Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer (NCT07193394) | Institut Curie | 2026-01-31 |
| BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer (NCT05977036) | Washington University School of Medicine | 2024-09-25 |
| HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada (NCT06386263) | AstraZeneca | 2024-04-22 |
| DESTINY Breast Respond HER2-(Ultra)Low Europe (NCT05945732) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-10-24 |
| A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer (NCT04872608) | Memorial Sloan Kettering Cancer Center | 2021-09-09 |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (NCT04042051) | Cancer Trials Ireland | 2019-11-12 |
Track Unresectable Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.